We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
How to use a quasi-experimental study to evaluate your digital health product.
How to use an ethnographic study to evaluate your digital health product.
How to use a before-and-after study to evaluate your digital health product.
How to use an interrupted time series to evaluate your digital health product.
How to use an economic evaluation to evaluate your digital health product.
How to use a cost benefit analysis to evaluate your digital health product.
How to use a case-control study to evaluate your digital health product.
How to use a cost utility analysis to evaluate your digital health product.
Apply to study English language in the UK with a Short-term study visa. Check fees, eligibility, documents you need and how to apply.
How to use interviews to evaluate your digital health product.
Transport analysis guidance (TAG) provides information on the role of transport modelling and appraisal.
How to use a patient-reported outcomes and experiences study to evaluate your digital health product.
Helping public health practitioners conducting evaluations – developing a logic model to represent how your intervention works.
How the UK's strategic export controls apply to academics, university researchers and their institutions, and when an export licence is needed.
Guidance, trends and projects to inform and support government officials to think strategically about the future.
Evidence base of long-term trends for UK policy makers, Spring 2021.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine etrasimod (Velsipity) to treat people with moderately to severely active ulcerative colitis.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).